top of page

Paccal Vet Vaccine Administers Its First Dose, Signaling Hope for Canine Hemangiosarcoma Treatment

In another milestone for Hemangiosarcoma vaccine development, Vivesto AB - a Swedish oncology-focused development company - has officially dosed the first patient in its Paccal Vet open-label pilot clinical trial for dogs with splenic Hemangiosarcoma following splenectomy. 

a dog stares intently at a vaccine that a veterinarian is holding

The trial will include four treatment cycles and investigate two cohorts with a maximum of 23 patients at six clinical sites in Washington and Oregon. The drug candidate - Paclitaxel micellar - is a chemotherapy medication that destroys fast-dividing cancer cells in human cancers such as ovary, breast, and cell lung.

If promising results arise, a pivotal study will be the next step to confirm the initial findings and gather further evidence on the safety and efficacy of Paccal Vet on canine splenic Hemangiosarcoma. The patients will receive their vaccine dose in early 2024, following a planned interim analysis in the second half of 2024.

Paccal Vet, formulated with the company's proprietary XR-17 technology, has shown safety in various types of cancer in dogs. The absence of solvent cremophor, which dogs are notably sensitive to, may reduce the risk of grave side effects and death associated with the treatment. The drug does not require the addition of human albumin, which can cause hypersensitivity reactions and reduced treatment effectiveness in dogs going through chemotherapy. 

Previous clinical studies by Vivesto have demonstrated safety in more than 300 dogs. Also, anti-tumor activity has materialized in dogs with squamous cell carcinoma and non-resectable mammary carcinoma of stage III-V.

Vivesto aims to offer new treatment options for hard-to-treat cancers with major medical needs and significant market potential for both humans and animals.  


bottom of page